Australia's most trusted
source of pharma news
Posted 14 May 2025 AM
With a five-strong portfolio of drugs now being commercialised across the country, Jazz Pharmaceuticals has well and truly signalled its commitment to Australia with the company’s ANZ General Manager, Eilis Quinn, sharing what’s been going on behind the scenes.
The latest treatment to reach Australia is Enrylaze, a new Erwinia-derived asparaginase approved by the TGA in April for use as a component of a multi-agent chemotherapeutic regimen for the treatment of Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) in adult and paediatric patients (one month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.